Experiments with graphenes indicate potential for saving millions of human lives

18 January 2016
graphene-big

Investigations of graphene properties for their use as enterosorbents have been performed in SM Kirov Military Medicine Academy in Russia. The research has been carried out under the leadership of Kirsan - Petrik Laboratory of the Future transcorporation.

The investigations were performed on animals in the conditions of acute and rapidly growing renal disease, caused by surgical removal of both kidneys from the animals. All surgical manipulations were executed with rats being in the state of ether anesthesia, taking into account the standards as per the European convention for the protection of vertebrate animals used for experimental and other scientific purposes.

It has been shown that on the background of growing uremic intoxication the oral administration of a graphene substance will double the survival rate of rats as compared to the reference group of animals, to which the substance was not administered.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical